Melanoma Clinical Trials

A listing of Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 749 clinical trials
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

With the introduction of checkpoint inhibitors substantial improvements have been made in the treatment of malignant melanoma (MM). Despite this still a a subset of patients, approximately 50

  • 20 Sep, 2021
  • 1 location
Adjuvant Nivolumab Treatment in Stage II (IIA IIB IIC) High-risk Melanoma

. However, to subdivide stage II melanoma patients into having a low or high risk for relapse further methods are needed. This clinical trial will evaluate whether adjuvant nivolumab treatment will

  • 18 Aug, 2021
  • 22 locations
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

+ nivolumab + ipilimumab in IFN-gamma signature low patients with de-novo or recurrent macroscopic stage III cutaneous or unknown primary melanoma. The trial will include 45 stage III cutaneous or

  • 25 Jan, 2021
  • 1 location
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

primary melanoma patients. Patients will be randomized 1:1 to receive either 2 cycles of neoadjuvant ipilimumab 80 mg + nivolumab 240 mg every 3 weeks followed by a total lymph node dissection (TLND) and

  • 25 Aug, 2021
  • 18 locations
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III Resectable Melanoma

Approximately 50 ABA+ subjects with resectable, Stage III (IIIB, IIIC, or IIID) melanoma will be included in the study and randomized in a 3:2 ratio to neoadjuvant treatment with Imprime PGG

  • 12 Sep, 2021
  • 4 locations
  • 24 Jan, 2021
  • 22 Jan, 2021
  • 7 locations
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Single arm study with dose escalation Phase Ib cohort followed by a Phase II cohort. PAC-1 (PO) will be given daily on Days 1 through 21 of each cycle (28-day cycle). Entrectinib (PO) will be given daily on Days 1 through 28 of each cycle. Response will be evaluated after …

  • 22 Aug, 2021
  • 1 location
Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)

of care in patients with metastatic UM. Supportive care in patients with metastatic Uveal Melanoma (UM)

  • 02 Feb, 2021
  • 2 locations
A Study to Assess LBL-007 in Combination With Toripalimab in Subjects With Advanced Melanoma

efficacy of LBL-007 in combination with Toripalimab in the treatment of unresectable or metastatic melanoma(including Cutaneous melanoma, Acral melanoma, Mucosal melanoma, and melanoma of unknown primary

  • 07 Jun, 2021
  • 3 locations